Clinical trialCLINICALTRIALSYesterday
Researchers are testing a new cancer drug called sutetinib maleate in people with advanced lung cancer that has specific uncommon genetic mutations. This is a Phase 2 trial, meaning the drug has already been tested in a small group and now researchers want to see if it works better and remains safe in a larger group of 66 patients. The study is currently accepting new participants.
WHY IT MATTERSIf you have metastatic or locally advanced non-small cell lung cancer with uncommon EGFR mutations, this trial offers access to a potentially new treatment option that may not yet be available outside of clinical research.
Clinical trialCLINICALTRIALSYesterday
Researchers are testing a new drug called BH-30643 for advanced lung cancer patients whose tumors have specific genetic mutations (EGFR or HER2). The study will first figure out the right dose and watch for side effects, then test how well the drug works against the cancer. About 266 patients will participate across multiple hospitals.
WHY IT MATTERSThis trial is now actively recruiting patients with EGFR and/or HER2-mutated advanced NSCLC — if you have this genetic profile and have exhausted standard treatments, you may be eligible to access a potentially new treatment option.
Clinical trialCLINICALTRIALS4 days ago
Researchers are looking for patients with advanced lung cancer (stage III) that cannot be removed with surgery and has unusual genetic mutations. The study will test whether giving patients targeted drugs based on their specific genetic mutation, followed by surgery, works better than standard treatment. About 120 patients will participate in this research.
WHY IT MATTERSIf you have unresectable stage III NSCLC with a rare mutation, this trial offers access to personalized treatment tailored to your specific genetic profile before surgery—an approach not yet widely available outside research settings.
Clinical trialCLINICALTRIALS5 days ago
Researchers are looking for adults and children with certain immune system disorders to join a study. The immune system normally helps your body fight infections, but in some people it doesn't work properly, causing frequent infections and other health problems. This study wants to understand why some immune systems fail and how to help people with these conditions. Relatives of affected people may also be able to join.
WHY IT MATTERSThis trial is actively recruiting 500 participants with four specific genetic immune disorders (PI3KCD, CTLA4, STAT3GOF, and MAGT1 deficiency) — if you or a family member has one of these diagnoses, you may be eligible to enroll now and contribute to understanding these rare conditions.
Clinical trialCLINICALTRIALS5 days ago
Williams syndrome is a rare genetic condition that affects about 1 in every 8,000 to 12,000 people. It happens when a person is missing a small section of DNA on chromosome 7, which includes the gene that makes elastin (a protein that helps blood vessels stretch). This causes distinctive facial features and heart and blood vessel problems. Researchers are now recruiting 1,099 people with Williams syndrome or a related heart condition called supravalvular aortic stenosis to donate DNA and tissue samples to help scientists better understand these conditions.
WHY IT MATTERSThis actively recruiting biobank offers Williams syndrome and SVAS patients a direct way to contribute DNA and tissue samples to NHLBI-sponsored research that could accelerate understanding of the genetic causes and lead to new treatments.